Figure legends
Table 1. Demographics of study subjects.
Table 2. Levels of 15-HETE and TXB2 in subjects
in the validation phase and asthmatic subjects stratified by severity
Figure 1. ROC analysis of exhaled 15-HETE,
TXB2, FeNO and Δ%FEV1.
Figure 2. Changes in the levels of FeNO, FEV1and eicosanoid species during exacerbation and convalescence. The levels
of (A) FeNO, (B) FEV1, (C) 15-HETE and (D)
TXB2 during acute exacerbation (AE) and after treatment
(C, convalescence) in a total of 75 children with asthma. Each line
represents each individual sample. Note: All p-values were adjusted for
multiple testing by Holm methods.
Figure 3. Changes in the levels of TXB2 and
15-HETE during exacerbation and convalescence in subjects according to
the top 30%, middle 40%, and bottom 30% (as determined at the
exacerbation levels). FA denotes the between-subjects main effect of
stratified eicosanoid levels during exacerbation; FB denotes the
within-subjects main effect of phasic change; FAXB denotes the
interaction of FA and FB variables.